UK Government Looking to Drive Efficiency of Healthcare Spending – KOL Perspectives in Bioworld Medtech
“The way to bring the NHS back to its former glory is to focus on driving efficiency” says Ali Pashazadeh, Treehill Partners CEO in a Bioworld Medtech article on “UK Government Abolishes NHS England“: https://www.bioworld.com/articles/717973-uk-government-abolishes-nhs-england (subscription required)
Roundtable Discussion in The Medicine Maker
“It is only by asking fundamental questions about the way we have done things in the past, understanding where the inefficiencies are, and how we can do things better, that the sector will advance.” Ali Pashazadeh, Treehill Partners CEO, shares his views along other industry leaders in The Medicine Maker roundtable discussion. Read on: https://themedicinemaker.com/business-regulation/bidens-legacy-trumps-agenda-part-1 […]
What can we expect the US life sciences sector to look like over the course of the next four years…
… as Donald Trump takes up his presidency? The election outcome has certainly sparked more discussion than we typically see during an administration change. Traditionally, there’s a transition period with expectations of continuity, but this time feels different. The team of The Medicine Maker have discussed with Ali Pashazadeh, Treehill Partners CEO – read the […]
What Does 2024 Hold For Biopharma? Treehill Partners featured in Scrip
Treehill Partners featured amongst prominent KOLs in Part 2 of Scrip’s 2024 biopharma outlook interview, discussing funding environment, M&A, and partnering. Read the article on Scrip: https://scrip.citeline.com/SC149635/Scrip-AsksWhat-Does-2024-Hold-For-Biopharma-Part-2-The-Funding-Environment-MA-And-Partnering